2. Havens J.C., Maibach H.I. Rosacea. Springer Nature Switzerland AG. 2000. 152 р.

3. Rueda L.J., Motta A., Pabon J.G., et al. Epidemiology of rosacea in Colombia. Int J Dermatol. 2017;56(5):510–13. doi: 10.1111/ ijd.13491.

4. Lee J.B., Moon J., Moon K.R., et al. Epidemiological and clinical features of rosacea in Korea: a multicenter cross-sectional study. J Dermatol. 2018;45(5):546–53. doi: 10.1111/1346- 8138.14281.

5. Wollina U., Verma S.B. Rosacea and rhinophyma: not curse of the Celts but Indo Eurasians. J Cosmet Dermatol. 2009;8(3):234–35. doi: 10.1111/j.1473-2165.2009.00456.x.

6. Gallo R.L., Granstein R.D., Kang S., et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78(1):148–55. doi: 10.1016/j. jaad.2017.08.037.

7. Yusupova L.A. Level sL-selectin in blood serum of patients with schizophrenia comorbidity pyoderma. Eur J Natural History. 2013;3:19–20.

8. Юсупова Л.А. Современное состояние проблемы эксфолиативного дерматита. Лечащий врач. 2019;11:6–8.

9. Юсупова Л.А., Мингазетдинова Н.И. Современное состояние проблемы сухой кожи. Лечащий врач. 2014;5:41.

10. Steinhoff M., Schauber J., Leyden J.J. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013;69:15–26. doi: 10.1016/j.jaad.2013.04.045.

11. Юсупова Л.А. Современный взгляд на проблему старения кожи. Лечащий врач. 2017;6:75.

12. Buddenkotte J., Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res. 2018;7. URL: https://f1000research.com/ articles/7-1885/v1

13. Al-Dabagh A., Davis S.A., McMichael A.J., et al. Rosacea in skin of color: not a rare diagnosis. Dermatol Online J. 2014;20.

14. Aldrich N. Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins. JAMA. Dermatol. 2015;151:1213–19. doi: 10.1001/jamadermatol.2015.2230.

15. Chang A.L.S., Raber I., Xu J., Li R., et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015;135(6):1548–55. doi: 10.1038/ jid.2015.53.

16. Woo Y.R., Lim J.H., Cho D.H., et al. Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci. 2016;17(9):1562. doi: 10.3390/ ijms17091562.

17. Schwab V.D. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:53–62. doi: 10.1038/jidsymp.2011.6.

18. Madva E.N., Granstein R.D. Nerve-derived transmitters including peptides influence cutaneous immunology. Brain Behav Immun. 2013;34:1–10. doi: 10.1016/j. bbi.2013.03.006.

19. Ahn C.S., Huang W.W. Rosacea pathogenesis. Dermatol Clin. 2018;36:81–6. doi: 10.1016/j. det.2017.11.001.

20. Azimi E. Dual action of neurokinin-1 antagonists on Mas-related GPCRs. JCI Insight. 2016;1(16):e89362. doi: 10.1172/jci. insight.89362.

21. Yu Y. LL-37-induced human mast cell activa¬tion through G protein-coupled receptor MrgX2. Int Immunopharmacol. 2017;49:6–12. Doi:10.1016/j.intimp.2017.05.016.

22. Muto Y. Mast cells are key mediators of cathelicidin-i nitiated skin inflammation in rosacea. J Invest Dermatol. 2014;134:2728–36. doi: 10.1038/jid.2014.222.

23. Mascarenhas N.L., Wang Z., Chang Y.L., et al. TRPV4 mediates mast cell activation in cathelicidin-induced rosacea inflammation. J Invest Dermatol. 2017;137:972–75. doi: 10.1016/j.jid.2016.10.046.

24. Moore C. UVB radiation generates sunburn pain and affects skin by activating epidermal TRPV4 ion channels and triggering endothelin-1 signaling. Proc Natl Acad Sci USA. 2013;110:E3225–34. doi: 10.1073/pnas.1312933110.

25. Anderson C.A., Boucher G., Lees C.W., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43(3):246–52. doi: 10.1038/ng.764.

26. Aponte J.L., Chiano M.N., Yerges-Armstrong L.M., et al. Assessment of rosacea symptom severity by genome-wide association study and expression analysis highlights immuno-inflammatory and skin pigmentation genes. Hum Mol Genet. 2018;27(15):2762–72. doi: 10.1093/hmg/ ddy184.

27. Awosika O., Oussedik E. Genetic predisposition to rosacea. Dermatol Clin. 2018;36(2):87–92. doi: 10.1016/j.det.2017.11.002.

28. Gallo R.L., Granstein R.D., Kang S., et al.Rosacea comorbidities and future research: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78(1):167–70. doi: 10.1016/j. jaad.2017.06.150.

29. Rainer B.M., Fischer A.H., Luz Felipe et al. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study. J Am Acad Dermatol. 2015;73(4):604–8. doi: 10.1016/j. jaad.2015.07.009.

30. Egeberg A., Hansen P.R., Gislason G.H., et al. Clustering of autoimmune diseases in patients with rosacea. J Am Acad Dermatol. 2016;74(4):667– 72. doi: 10.1016/j.jaad.2015.11.004.

31. Lyon S., Majewski S., Guido N., et al. LB766 Parkinson’s disease association with rosacea: a large, single center, retrospective study. J Invest Dermatol. 2016;136(8):B3.

32. Li W.Q., Zhang M., Danby F.W., et al. Personal history of rosacea and risk of incidentcancer among women in the US. Br J Cancer. 2015;113(3):520– 23. doi: 10.1038/bjc.2015.217.

33. Gallo R.L., Granstein R.D., Kang S., et al. Rosacea comorbidities and future research: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78(1):167–70. doi: 10.1016/j.jaad.2017.06.150